Literature DB >> 11792237

Barrett's Esophagus, a Complication of GERD.

Richard E. Sampliner1.   

Abstract

The treatment of patients with Barrett's esophagus is similar to that of any patient with underlying gastroesophageal reflux disease (GERD). The treatment of reflux includes medical and surgical therapy. A key component of medical therapy is the use of a proton pump inhibitor to treat the underlying GERD. The major controversy is whether the end point of therapy should be the control of reflux symptoms or the control of esophageal pH. When controlling reflux symptoms with proton pump inhibitor therapy, it is important to eliminate all of the symptoms of reflux. An alternative to medical therapy is surgical fundoplication, which is currently performed laparoscopically. Fundoplication may be indicated when a patient has persistent regurgitation even while on proton pump inhibitor therapy. An individual patient also may choose fundoplication, preferring surgical intervention to taking medication long term on a daily basis. Patients with Barrett's esophagus also have the risk of the developing of adenocarcinoma of the esophagus. Therefore, there is an additional goal in the therapy for individuals with Barrett's to prevent progression to adenocarcinoma. The standard approach to the issue of the premalignant nature of Barrett's esophagus is surveillance endoscopy with biopsy in order to detect dysplasia, a cytologic and architectural histologic change. Dysplasia is the first step in the neoplastic process, an early stage offering the opportunity of intervention and longer-term survival.

Entities:  

Year:  2002        PMID: 11792237     DOI: 10.1007/s11938-002-0006-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  31 in total

1.  Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole.

Authors:  H Schulz; S Miehlke; D Antos; K U Schentke; M Vieth; M Stolte; E Bayerdörffer
Journal:  Gastrointest Endosc       Date:  2000-06       Impact factor: 9.427

2.  Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study.

Authors:  R E Sampliner; D Faigel; M B Fennerty; D Lieberman; A Ippoliti; K Lewin; W M Weinstein
Journal:  Gastrointest Endosc       Date:  2001-05       Impact factor: 9.427

3.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.

Authors:  E C Klinkenberg-Knol; F Nelis; J Dent; P Snel; B Mitchell; P Prichard; D Lloyd; N Havu; M H Frame; J Romàn; A Walan
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

4.  Long-term outcome of antireflux surgery in patients with Barrett's esophagus.

Authors:  W L Hofstetter; J H Peters; T R DeMeester; J A Hagen; S R DeMeester; P F Crookes; P Tsai; F Banki; C G Bremner
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

5.  Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus.

Authors:  P K Nijhawan; K K Wang
Journal:  Gastrointest Endosc       Date:  2000-09       Impact factor: 9.427

6.  Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole.

Authors:  A Malesci; V Savarino; P Zentilin; M Belicchi; G S Mela; G Lapertosa; P Bocchia; G Ronchi; M Franceschi
Journal:  Gastrointest Endosc       Date:  1996-12       Impact factor: 9.427

7.  Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.

Authors:  F T Peters; S Ganesh; E J Kuipers; W J Sluiter; E C Klinkenberg-Knol; C B Lamers; J H Kleibeuker
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

8.  Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.

Authors:  C Winters; T J Spurling; S J Chobanian; D J Curtis; R L Esposito; J F Hacker; D A Johnson; D F Cruess; J D Cotelingam; M S Gurney
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

9.  Impact of hospital volume on operative mortality for major cancer surgery.

Authors:  C B Begg; L D Cramer; W J Hoskins; M F Brennan
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

10.  Aspirin and reduced risk of esophageal carcinoma.

Authors:  E M Funkhouser; G B Sharp
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

View more
  3 in total

1.  Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett's esophagus.

Authors:  Bronia Alashkar; Ashley L Faulx; Ashley Hepner; Richard Pulice; Srikrishna Vemana; Katarina B Greer; Gerard A Isenberg; Yngve Falck-Ytter; Amitabh Chak
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-23       Impact factor: 11.382

Review 2.  The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: a systematic review.

Authors:  Zhannat Nurgalieva; Angus Lowrey; Hashem B El-Serag
Journal:  Dig Dis Sci       Date:  2007-03-21       Impact factor: 3.487

3.  Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy.

Authors:  Jennifer R Kramer; Jennifer Arney; John Chen; Peter Richardson; Zhigang Duan; Richard L Street; Marilyn Hinojosa-Lindsey; Aanand D Naik; Hashem B El-Serag
Journal:  BMC Health Serv Res       Date:  2012-08-28       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.